Hangzhou Kunyu Pharmaceutical

Hangzhou Kunyu Pharmaceutical appears to be a China-based private biopharmaceutical company focused on early-stage oncology drug discovery. Publicly available sources link the company to the preclinical asset KY102, described as a Glypican-3-targeting nanobody drug conjugate carrying a topoisomerase I inhibitor payload for hepatocellular carcinoma and other GPC3-positive tumors. Corporate registry data also show an active operating entity in Hangzhou, Zhejiang engaged in medical research, experimental development, and pharmaceutical import/export-related activities. The company seems to be very early stage, with limited public disclosure beyond registry information and pipeline references in commercial biopharma databases and conference-related coverage.